Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cytk · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cytokinetics, Incorporated (CYTK) measures how much investors pay for each dollar of the company's trailing earnings. CYTK's current PE ratio of N/A is calculated by dividing its stock price of $68.84 by its TTM earnings per share of -$6.73.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cytokinetics, IncorporatedYou CYTK | $8.6B | N/A | — | -$6.73 |
 Abivax S.A. ABVX | $6.7B | N/A | — | -$4.83 |
 Axsome Therapeutics, Inc. AXSM | $12.2B | N/A | — | -$3.68 |
 Corcept Therapeutics Incorporated CORT | $8.0B | 36.27x | +17.5% | $0.96 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Halozyme Therapeutics, Inc. HALO | $8.4B | 25.45x | -17.5% | $2.64 |
 Jazz Pharmaceuticals plc JAZZ | $14.7B | N/A | — | -$5.84 |
Industry Average 2 peers with valid PE | — | 30.86x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-6.54 | — | |
2024-12-31 FY2024 | — | $-5.26 | — | |
2023-12-31 FY2023 | — | $-5.45 | — | |
2022-12-31 FY2022 | — | $-4.33 | — | |
2021-12-31 FY2021 | — | $-2.80 | — | |
2020-12-31 FY2020 | — | $-1.97 | — | |
2019-12-31 FY2019 | — | $-2.11 | — | |
2018-12-31 FY2018 | — | $-1.95 | — | |
2017-12-31 FY2017 | — | $-2.59 | — | |
2016-12-31 FY2016 | 29.50x | $0.41 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cytokinetics, Incorporated (CYTK) measures how much investors pay for each dollar of the company's trailing earnings. CYTK's current PE ratio of N/A is calculated by dividing its stock price of $68.84 by its TTM earnings per share of -$6.73.
Frequently asked questions
CYTK pe ratio · 6 questionsCYTK's current PE ratio is N/A as of 2026-06-08, based on a stock price of $68.84 and TTM EPS of -$6.73. Data sourced from Financial Modeling Prep via CYTK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cytokinetics, Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08